Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
+11.71 (4.59%)
After Hours: 266.20 -0.50 (-0.19%)
May 4, 5:06PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 253.15 - 272.75
52 week 128.50 - 349.08
Open 254.10
Vol / Avg. 549,176.00/622,861.00
Mkt cap 6.11B
P/E     -
Div/yield     -
EPS -13.75
Shares 22.64M
Beta     -
Inst. own 67%
Jul 17, 2015
Intercept Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 5, 2015
Q1 2015 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 20, 2015
Intercept Pharmaceuticals Inc Investor Meeting at AASLD Colloquium
Mar 3, 2015
Intercept Pharmaceuticals Inc at Cowen Health Care Conference
Mar 2, 2015
Q4 2014 Intercept Pharmaceuticals Inc Earnings Release
Mar 2, 2015
Q4 2014 Intercept Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -7818.43% -16262.21%
Operating margin -7887.47% -6497.98%
EBITD margin - -6472.56%
Return on average assets -51.72% -140.05%
Return on average equity -56.79% -180.80%
Employees 136 -
CDP Score - -


450 W 15th St Ste 505
NEW YORK, NY 10011-7082
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company�s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA selectively binds to and induces activity in the farnesoid X receptor, or FXR, which has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. It is conducting a Phase III clinical trial of OCA in PBC. Its other products are INT-767 and INT-777.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Daniel P. Regan Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 40
Bio & Compensation  - Reuters
Sanj K. Patel Independent Director
Age: 44
Bio & Compensation  - Reuters